You are here

  • Home
  • Archive
  • Volume 33, Issue Suppl 4
  • SO012/#773  Comparison the outcomes of large bowel surgery during maximal cytoreductive surgery for advanced ovarian cancer between gynecologic oncology specialist and general surgeon: gorilla-3006

Article Text

Article menu

Download PDFPDF

Focused Plenary 02: Surgery
AS11. Ovarian cancer
SO012/#773  Comparison the outcomes of large bowel surgery during maximal cytoreductive surgery for advanced ovarian cancer between gynecologic oncology specialist and general surgeon: gorilla-3006
Free
  1. Myeong-Seon Kim1,
  2. A Jin Lee2,
  3. Seung-Hyuk Shim2,
  4. Eunbi Jang3,
  5. Nam Kyeong Kim4,
  6. Yeorae Kim4,
  7. Dong Hoon Suh5,
  8. Jeeyeon Kim6,
  9. Tae-Wook Kong6,
  10. Suk-Joon Chang6,
  11. Dong Won Hwang7,
  12. Soo Jin Park7,
  13. Hee Seung Kim7,
  14. Ji Geun Yoo8,
  15. Sung Jong Lee9 and
  16. Yoo Young Lee10
  1. 1St.Vincent’s Hospital, The Catholic university of Korea, Obgy, Seoul, Korea, Republic of
  2. 2Konkuk University Hospital, Obstetrics and Gynecology, Seoul, Korea, Republic of
  3. 3Konkuk University School of Medicine, Obstetrics and Gynecology, Seoul, Korea, Republic of
  4. 4Seoul National University Bundang Hospital, Department of Obstetrics and Gynecology, Seongnam, Korea, Republic of
  5. 5Seoul National University Bundang Hospital, Department of Obstetrics and Gynecology, Seongnam-Si, Korea, Republic of
  6. 6Ajou University Medical Center, Obstetrics and Gynecology, Suwon, Korea, Republic of
  7. 7Seoul National University Hospital, Obstetrics and Gynecology, Seoul, Korea, Republic of
  8. 8Daejeon St. Mary’s hospital, Obstetrics and Gynecology, Daejeon, Korea, Republic of
  9. 9Seoul St. Mary’s Hospital, Obstetrics and Gynecology, Seoul, Korea, Republic of
  10. 10Samsung Medical Center, Obstetrics and Gynecology, Seoul, Korea, Republic of

Abstract

Introduction We report the oncological outcomes in patients with advanced ovarian cancer who had bowel surgery which was performed by gynecologic oncologist (GO) during maximal cytoreductive surgery and compared the outcomes with those of bowel surgery performed by general surgeons (GS).

Methods Patients who were FIGO stage I-IV ovarian cancer and had bowel surgery during maximal cytoreductive surgery were eligible. Patients were divided into two groups according to whether bowel resection was performed by GO or GS. In both groups, GO were mainly involved in debulking procedures. Perioperative and survival outcomes were compared between two groups.

Results A total of 439 patients were eligible. 82 patients received large bowel surgery by GO, and 357 patients by GS. The proportion of patients who underwent PDS was higher in GO group than in GS group (80.5% vs 70.9%, p =0.057). The residual disease after maximal cytoreductive surgery did not differ between two groups (P=0.281). The distribution of anastomotic sites of large bowel resections were not different between two groups. There was no significant differences in progression-free and overall survival between two groups. In a multi-variate Cox analysis, Time of surgery (PDS vs. IDS, HR 2.124, 95%CI 1.037–4.348, p=0.039) and residual diseases (R0 vs. non-R0, HR 2.133, 95%CI 1.001–4.547, p=0.050) were associated with survivals. Bowel surgery specific complications did not differ between two groups.

Conclusion/Implications Large bowel surgery performed by GO was feasible and safe. We showed equivalent oncological outcomes when compared with those by GS during maximal cytoreductive surgery for advanced ovarian cancer.

https://doi.org/10.1136/ijgc-2023-IGCS.26

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.